Genmab A/S reports results for the quarter ended December 31 - Earnings Summary

Genmab A/S

12/02/2025 17:37

* Genmab A/S  GMAB.CO  reported quarterly adjusted earnings
of
DKK59.64​​ per share for the quarter ended December 31, higher
than the same quarter last year, when the company reported EPS
of DKK9.67.  The mean expectation of eleven analysts for the
quarter was for earnings of DKK25.52 per share. Wall Street
expected results to range from DKK22.54  to DKK28.80 per share.
    * Revenue rose 37.7% to DKK6.44 billion from a year ago;
analysts
expected DKK6.41 billion. 
    * Genmab A/S's reported EPS for the quarter was DKK59.64​.
    * The company reported quarterly net income of DKK3.85
billion.
    * Genmab A/S shares had fallen by 8.0% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4% in
the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Genmab A/S is
DKK2,350.00 
This summary was machine generated from LSEG data February 12 at
05:36 p.m. UTC. ​All figures in Danish crowns unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      25.52          59.64          Beat
 Sep. 30 2024      21.89          19.81          Missed
 Jun. 30 2024      20.56          21.70          Beat
 Mar. 31 2024      11.83          20.18          Beat